Windward Bio completes IPO on Nasdaq
Niederer Kraft Frey advised Windward Bio Group AG in connection with its initial public offering (IPO) and the listing of its shares on the Nasdaq Global Select Market.
On 12 November 2026, Windward Bio Group AG, a Basel-based clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, priced its initial public offering at USD 17 per share. Its shares began trading on the Nasdaq Global Select Market on 13 November 2026 under the ticker symbol “WWB”. The IPO raised gross proceeds of approximately USD 201 million (including greenshoe). Together with a concurrent USD 50 million private placement of shares and pre-funded warrants to Sanofi, total gross proceeds amount to approximately USD 251 million. At the close of the first trading day, Windward Bio had a market capitalization of approximately USD 1.7 billion.
The NKF team includes Transactions partners Andreas Müller and Margrit Marti, working with associates Lucas Forrer and Oliver Kneubühl and junior associate Melina Kalias (all Transactions / Capital Markets), senior associate Arbnor Sheholli (Tax) and counsel Livia Keller (Employment / Executive Compensation). Cooley LLP, led by Brandon Fenn, acted as US counsel.